<DOC>
	<DOC>NCT00154245</DOC>
	<brief_summary>The study is a one-year prospective, open-label, safety and efficacy study. De novo renal transplant recipients will be receiving cyclosporine, 1.44g EC-MPS (720 mg b.i.d.), and corticosteroids .The study will consist of a 12-month open-label treatment period on EC-MPS.</brief_summary>
	<brief_title>A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males and females aged 1875 years. Recipients of de novo cadaveric, living unrelated or living related kidney transplants Multiorgan recipients (e.g. kidney and pancreas) or previous transplant with any organ. Patients who are recipients of ABO incompatible transplants. Patients with a historical or current peak PRA of 50%. Patients with already existing antibodies against the HLAtype of the receiving transplant. Evidence of severe liver disease (incl. abnormal liver profile i.e. AST, ALT or total bilirubin 3 times UNL). Patients who are HIV or Hepatitis B surface antigen positive. Patients with any known hypersensitivity to mycophenolic acid, MMF, ECMPS, other components of the formulation (e.g. lactose). Patients with thrombocytopenia (75,000/mm3), with an absolute neutrophil count of &lt; 1,500/mm3, and/or leukocytopenia (&lt; 2,500/mm3), and/or hemoglobin &lt; 6 g/dL at Screening or Baseline. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Enteric-coated mycophenolate sodium, transplantation, de novo, cyclosporine</keyword>
</DOC>